38.81

2.51% 0.95

Verona Pharma Plc Adr (VRNA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$37.86

Offen:

$38.11

24-Stunden-Volumen:

1.23M

Relative Volume:

1.23

Marktkapitalisierung:

$3.18B

Einnahmen:

Nettoeinkommen (Verlust:

$-153.72M

KGV:

-69.30

EPS:

-0.56

Netto-Cashflow:

$-103.81M

1W Leistung:

+8.83%

1M Leistung:

+11.30%

6M Leistung:

+208.02%

1J Leistung:

+176.23%

1-Tages-Spanne:

$37.67

$39.25

1-Wochen-Bereich:

$34.51

$39.58

52-Wochen-Spanne:

$11.39

$40.13

Verona Pharma Plc Adr Stock (VRNA) Company Profile

Firmenname

Verona Pharma Plc Adr

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

011-44-0-2032834200

Adresse

3 MORE LONDON RIVERSIDE, LONDON

Mitarbeiter

Twitter

@VeronaPharma

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

VRNA's Discussions on Twitter

Vergleichen Sie VRNA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VRNA	38.81	3.18B	0	-153.72M	-103.81M	-0.56
VRTX	450.97	116.38B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	82.09B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.14B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.25B	3.30B	-501.07M	1.03B	11.54

Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-05-22	Fortgesetzt	Jefferies	Buy
2022-09-19	Fortgesetzt	Wedbush	Outperform
2022-08-26	Eingeleitet	Piper Sandler	Overweight
2021-09-13	Eingeleitet	H.C. Wainwright	Buy
2020-08-25	Eingeleitet	Jefferies	Buy
2020-08-10	Eingeleitet	Canaccord Genuity	Buy
2019-04-18	Eingeleitet	BTIG Research	Buy

Alle ansehen

Verona Pharma Plc Adr Aktie (VRNA) Neueste Nachrichten

Nov 07, 2024

Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com

Nov 07, 2024

Verona Pharma director David Ebsworth buys $188,880 in shares - Investing.com

Nov 07, 2024

Nov 05, 2024

Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com

Nov 05, 2024

Nov 04, 2024

Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria

Nov 04, 2024

Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India

Nov 04, 2024

Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria

Nov 04, 2024

Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa

Nov 04, 2024

Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK

Nov 04, 2024

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.

Nov 04, 2024

Oct 25, 2024

Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India

Oct 25, 2024

Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India

Oct 25, 2024

Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart

Oct 25, 2024

Oct 24, 2024

5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart

Oct 24, 2024

Oct 22, 2024

Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India

Oct 22, 2024

Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa

Oct 22, 2024

Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa

Oct 22, 2024

Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India

Oct 22, 2024

Oct 16, 2024

Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex

Oct 16, 2024

Oct 15, 2024